ArticleJournal of cachexia, sarcopenia and muscle2026
Skeletal Muscle Mass Modifies the Prognostic Impact of LDL Cholesterol in Chronic Heart Failure.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of triglyceride-cholesterol-body weight index with in-hospital mortality in critically ill patients with heart failure.Scientific reports · 2026Article
- Skeletal Muscle Mass Modifies the Prognostic Impact of LDL Cholesterol in Chronic Heart Failure.Journal of cachexia, sarcopenia and muscle · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDyslipidaemia is among the major risk factors for atherosclerotic cardiovascular disease. Paradoxically, higher cholesterol levels are associated with better survival in heart failure (HF) of any aetiology. Because cholesterol is an integral component of skeletal muscle structure, one possible explanation involves the interplay between lipid metabolism and skeletal muscle health. Using data from the Studies Investigating Comorbidities Aggravating Heart Failure, we investigated whether an association exists between low-density lipoprotein cholesterol (LDL-C) levels and all-cause mortality in patients with chronic HF in the context of skeletal muscle mass.
methodsA total of 241 patients with chronic HF (68 ± 11 years, 80% male, left ventricular ejection fraction 39% ± 13%) were enrolled. LDL-C levels were divided into low and high based on the median value (93 mg/dL). The appendicular skeletal muscle mass index (ASMI) was assessed using a dual-energy X-ray absorptiometry scan and divided into high and low based on the sex-specific median value (men = 7.97 kg/m
resultsDuring a median follow-up of 6.3 years, 95 patients (39%) died. There were differences in mortality between the four groups, with the highest mortality in patients with low LDL-C levels and low ASMI and the lowest mortality in patients with high LDL-C levels and high ASMI (p = 0.002, by log-rank). The low LDL-C group had higher mortality compared with the high LDL-C group (46% vs. 33%, p = 0.01, by log-rank). Multivariate Cox proportional hazard analysis confirmed the association between the low LDL-C group and higher mortality (adjusted hazard ratio [aHR] 1.65 [1.00-2.72], p = 0.04). This prognostic impact of low LDL-C appeared greater in the low ASMI group than in the high ASMI group (56% vs. 37%, p = 0.01, and 36% vs. 28%, p = 0.28, by log-rank: p for interaction = 0.47). In the low ASMI group, lower LDL-C levels were predictors of mortality in multivariate Cox proportional hazard models (aHR 1.46-1.48 per 1 SD decrease in LDL-C, all p < 0.05).
conclusionsIn patients with chronic HF, lower LDL-C levels were associated with higher mortality, especially in the low ASMI group. These findings suggest that low cholesterol levels may exacerbate skeletal muscle loss, potentially creating a vicious cycle that worsens patient outcomes. Lipid-modulating strategies could help mitigate muscle wasting in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.